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ABSTRACT

The present invention relates to methods for protecting
against damage caused by radiation and/or chemotherapy,
and methods for treating bone marrow damage by reducing/
inhibiting Latexin expression and/or Latexin activity. The
methods comprise administering to a subject in need thereof
a pharmaceutical composition comprising an antagonist that
reduces expression and/or activity of latexin, wherein
latexin is a latexin polynucleotide variant and/or a latexin
polypeptide variant that binds to the antagonist.

22 Claims, 4 Drawing Sheets
Specification includes a Sequence Listing.
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PROTECTION AGAINST IONIZING
RADIATION AND CHEMOTHERAPY
TOXICITY VIA LATEXIN REGULATION

radiation passes through a cell, its high energy causes
intracellular atoms and molecules to become excited, or
"ionized". This ionization can break chemical bonds, produce free radicals, and damage molecules (e.g. DNA, RNA,
proteins, and lipids), which are vital in biological processes.
The blood forming-organs, reproductive organs, digestive
organs, skin, bone and teeth are primary targets of radiation.
Among the tissues mentioned above, the blood system is
most sensitive to radiation due to its high turnover rate. In
mouse model, after exposure to irradiation, blood cell numbers drops precipitously (drop stage), reaching a nadir
around day 3 (nadir stage). Subsequently, the number of
blood cells begins to recover and reaches to a nearly normal
level around 30 days post irradiation (recovery stage).
The most critical period for a subject's survival after
radiation injury is within the first two weeks. For example,
if mice are exposed to 6-7Gy total body irradiation, about
the 5th or 6th day following exposure a few of the mice may
begin to appear lethargic and start to die. Daily mortality
increases to a peak between the 10th and 14 th day then
gradually subsides. After the 20 th day deaths are infrequent
and the surviving mice show evidence of recovery.
After exposure to ionizing radiation, radiation-induced
DNA damage immediately halts cell cycle progression (cell
cycle arrest). During the period of cell cycle arrest, DNA
repair machinery is triggered and begins to repair the
damage. If the repair is unsuccessful, the cells are removed
by a programmed cell death mechanism (apoptosis). HSC
apoptosis increases after radiation exposure. At the 7 th day
post 6.5Gy total body irradiation, which is the time-point
when the apoptotic rate reaches the peak, around 20% HSCs
(Lin-Sca-1 +c-Kit+cells) undergo apoptosis.
In some cells, the cell cycle arrest becomes permanent.
These cells lose their proliferation capacity and become
senescent. A study on human HSCs (CD133+ cells) demonstrated that, even though these cells were successfully
repaired, their ability to self-renew was permanently damaged. An increase in pl6Ink4 a expression on HSCs also
implies the induction of premature senescence in these cells.
In some circumstances, apoptosis and senescence do not
functionally remove all of the damaged cells. A small
number of cells survive radiation stress with chromosome
aberrations. These cells are dangerous due to their genomic
instability, and have potential to result in tumorigenesis in
the future.
Therefore, ionizing radiation induced-apoptosis is necessary to balance tumorigenesis prevention and organismal
survival. Low levels of apoptotic activity are beneficial to
tissue regeneration and may promote the restoration of
hematopoiesis when cells are exposed to ionizing radiation.

STATEMENT OF GOVERNMENT INTEREST
This invention has been made with Government support,
awarded by the National Center for Advancing Translational
Sciences, National Institutes of Health, grant number
KL2TR000116. The government has certain rights in the
invention.
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TECHNICAL FIELD
The present invention relates to methods for protecting
against damage caused by radiation and/or chemotherapy by
reducing/inhibiting Latexin expression and/or Latexin activity.
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BACKGROUND OF THE INVENTION

20

Hematopoiesis is a complex process for producing multiple and distinct lineages of blood-borne cells throughout
the life span of an organism. Hematopoietic stem cells
("HSCs") represent a subset of undifferentiated cells that
resides predominantly in the bone marrow of adult mammals. HSCs, as a population, are capable of self-renewal by
maintaining a sufficient number of HSCs within an organism's bone marrow as a reservoir of uncommitted cells that
can be further differentiated into various types of new blood
cells. Such newly generated blood cells emerge from the
bone marrow and enter the circulatory system in order to
continuously replace mature/aging circulating blood cell
types. The ability of HSCs, as a population, to differentiate
and to give rise to cells of multi-lineages is critical for the
preservation of an organism.
In order for the maintenance of steady-state hematopoiesis, a balance must be achieved between the rate of selfgeneration (i.e., for maintaining a steady supply of HSCs)
and the rate of differentiation (i.e., for replenishing senescent
cells). Hematopoiesis occurs as a developmental continuum
in that a given population of HSCs is representative of a
heterogeneous mixture of cells, mainly composed of longterm HSCs ("LT-HSCs") and short-term HSCs ("STHSCs"). LT-HSCs are stem cells that have the capacity for
self-renewal throughout the life span of an organism. However, ST-HSCs exhibit transient self-renewal properties for a
limited period of time (e.g., typically less than 8 weeks in a
mouse) prior to undergoing full differentiation. HSCs can
differentiate into hematopoietic progenitor cells ("HPCs")
that can further differentiate into clonogenic cells, or cells of
a single lineage. For example, the differentiation of common
lymphoid progenitors ("CLPs") can produce T lymphocytes
("T cells"), B lymphocytes ("B cells"), and natural killer
cells ("NKs"). The differentiation of common myeloid progenitors ("CMPs") can generate blood cells of other lineages, including erythrocytes, macrophages, granulocytes,
and platelets. The maintenance of mature blood-borne cells
in the peripheral circulation is critical for various processes,
including oxygen delivery and immunological protection.
Maintaining a stable supply of mature blood cells is
essential for nutrient supply, pathogen defense and tumor
surveillance in hematopoiesis. However, this homeostasis
can be perturbed by a DNA-damaging agent such as ionizing
radiation or chemotherapy. Ionizing radiation is a highfrequency radiation that has very high energy and the
capacity to remove an electron from an atom. When ionizing
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A method for protecting against hematopoietic stem cell
(HSC) damage caused by chemotherapy and/or radiation, in
which the subject is administered a pharmaceutical composition comprising an antagonist that reduces Latexin expression and/or Latexin activity.
BRIEF DESCRIPTION OF DRAWINGS
FIGS. lA and lB illustrate the Kaplan-Meier survival
curves of mice exposed to lethal total body irradiation and
the Kaplan-Meier survival curves of mice exposed to clinically relevant total body irradiation.
FIGS. 2A-2D illustrate the numbers of surviving LSK cell
in one femur compared between B6 and Lxn-/- mice that
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had been irradiated with a sub-lethal dose of irradiation (6.5
Gy), flow cytometric analysis showing expanded LSK, LK,
and LS cell populations at day 14 post-irradiation for both
Lxn-/- and B6 mice, the frequencies ofhematopoietic stem
and progenitor cells as determined by an in vitro colony
forming cell assay, and the numbers of surviving bone
marrow cells in one femur compared between B6 and
Lxn-/- mice that had been irradiated with a sub-lethal dose
of radiation.
FIGS. 3A-3E illustrate the counts of total leukocytes, the
counts of total neutrophils, the counts of total lymphocytes,
the counts of total platelets, and differentiated lineage cells
as measured by flow cytometer using lineage-specific antibodies (Gr-1, Mac-1, B220 and Thy-1) of B6 and Lxn-/mice that had been irradiated with a sub-lethal dose of
radiation.
FIGS. 4A-4C illustrate the flow cytometric analysis of
apoptotic cells on day 14 post-irradiation using Annexin-V
and DNA dye staining, analysis of apoptotic rate dynamics
(over 56 days post-irradiation) in LSK population, and the
apoptotic frequency of LSK, LK, LS and LIN- sub-populations in day 14 post-irradiation ofB6 and Lxn-/- mice that
had been irradiated with a sub-lethal dose of radiation.

HSCs include non-embryonic stem cells isolated from postnatal animals, which are known as adult stem cells. HSCs
are isolated from the bone marrows of mammals that are
capable of differentiating into ectodermal lineages of blood
cells. HSCs include undifferentiated stem cells that exhibit
a distinct profile of cell surface markers, including the
following combination of markers: Thy-1 10 Sca-1 + Lineagec-kit+; or CD15o+CD48- Sca-1+ Lineage- c-kit+; or Thy-1 10
CD150+ CD48- Sca-1+ Lineage- c-kit+ (Kiel et al. Cell,
Vol. 121, p. 1109-1121 (2005)). HSCs that express the
combination of human counterparts for these markers are
preferably contemplated. The following references are
herein incorporated by reference in their entirety: Cheshier
et al. PNAS Vol. 96, p. 3120-3125 (1999); Eckfeldt et al.
Nature, Vol. 6, p. 726-737 (2005); Wright et al. Science Vol.
94, p. 1933-1936 (2001); and Preston et al. J. Clin. Pathol.
Vol. 56, p. 86-96 (2003).
The term "Latexin" ("Lxn") refers to the Lxn gene,
isoforms/variants of the Lxn gene, and gene products
derived from the Lxn gene, including messenger RNA and
protein. The sense-strand of a human Latexin cDNA is
provided as SEQ ID NO: 1. A human Latexin protein
sequence is provided as SEQ ID NO:2. Latexin isoforms/
variants include genes containing exon sequences having at
least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%,
98%, or 99% sequence similarity to SEQ ID NO: 1; genes
containing ex on sequences having at least about 70%, 75%,
80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence
identity to SEQ ID NO: 1; those sequences encoded by genes
containing exon sequences having at least about 70%, 75%,
80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence
similarity to SEQ ID NO: 1; those sequences encoded by
genes containing exon sequences having at least about 70%,
75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%
sequence identity to SEQ ID NO: 1; those sequences having
at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%,
98%, or 99% sequence similarity to SEQ ID NO:2; and
those sequences having at least about 70%, 75%, 80%, 85%,
90%, 95%, 96%, 97%, 98%, or 99% sequence identity to
SEQ ID NO:2. Latexin isoforms/variants include mammalian homologs listed in Tables 1-3. Variants useful in the
methods of the present invention includes variants of SEQ
ID NO: 1 and/or SEQ ID NO:2 as described above, and in
some embodiments variants useful in the methods of the
present invention include the variants of SEQ ID NO: 1 or
SEQ ID NO:2 excluding the carboxypeptidase inhibitor
(CARIN) described in U.S. Pat. No. 5,998,373.
The term "antagonist" refers to any compound or composition that can inhibit the expression and/or the activity of
Latexin and Latexin isoforms, including sequence-specific
polynucleotides that can interfere with the transcription of
endogenous Latexin gene; sequence-specific polynucleotides that can interfere with the translation of Latexin
mRNA transcripts (e.g., siRNAs, ribozymes ); sequencespecific polypeptides that can interfere with the protein
stability ofLatexin, the enzymatic activity ofLatexin, and/or
the binding activity of Latexin with respect to substrates
and/or regulatory proteins; and small molecule compounds
that can interfere with the protein stability of Latexin, the
enzymatic activity of Latexin, and/or the binding activity of
Latexin. An effective antagonist can promote HSC proliferation by at least 25%, 30%, 35%, 40%, 45%, 50%, 55%,
60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%. An
effective antagonist can suppress HSC apoptosis by at least
25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%,
75%, 80%, 85%, 90%, 95%, or 100%.

DETAILED DESCRIPTION OF THE
INVENTION
It has been surprisingly discovered that down-regulating
Latexin (Lxn) protects hematopoietic progenitor and stem
cells from damage caused by ionizing radiation and/or
chemotherapy and accelerates hematopoietic and immunologic recovery.
It has also been surprisingly discovered that down-regulating Lxn suppresses radiation-induced apoptosis in
hematopoietic progenitor and stem cells.
It has also been surprisingly discovered that treating a
subject that could potentially be exposed to radiation (e.g. a
subject scheduled for radiation treatment, or a subject accidentally exposed to environmental radiation) with a pharmaceutical composition comprising an antagonist that
reduces Lxn expression and/or Lxn activity protects
hematopoietic progenitor and stem cells from potential
damage that could be caused by the radiation and accelerates
hematopoietic and immunologic recovery. The subject may
be a mammal, e.g., a primate, e.g., a human, a cow, pig, dog,
cat, rat or mouse.
These discoveries provide methods for protecting HSCs
in subjects, e.g., human patients, undergoing radiation
therapy, chemotherapy, or subjects that have been or could
be exposed to radiation (environmental, medical, or otherwise).
Definitions
As used throughout the specification and the appended
claims, the terms listed below have the following meanings,
wherein "a" means one or more:
The terms "hematopoietic stem cells" ("HSCs") refer to a
heterogeneous mixture of undifferentiated primitive stem
cells, mainly composed of long-term HSCs ("LT-HSCs")
and short-term HSCs ("ST-HSCs"). LT-HSCs are undifferentiated stem cells that have the capacity for self-renewal
throughout the life span of an organism. ST-HSCs are
undifferentiated stem cells that have the capacity for selfrenewal for a limited time prior to full differentiation into a
specific lineage. For example, HSCs can differentiate into
hematopoietic progenitor cells ("HPCs") that can further
differentiate into clonogenic cells, or cells of a single lineage, that represent a subset of a hematopoietic lineage.
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Protection of Radiation and/or Chemotherapy Damage
Described herein are methods for protecting against damage caused by radiation and/or chemotherapy, in which the
method comprises administering to a subject in need thereof
a pharmaceutical composition comprising an antagonist that
reduces Latexin expression and/or Latexin activity.
The present methods enable persons of skill in the art to
decrease apoptotic frequency of HSCs and/or to promote
HSC proliferation within the bone marrow of patients
affected by genotoxic stress, such as radiation or chemotherapy.
Subjects in need thereof include manmialian subjects that
have either already been exposed to radiation at levels
sufficient to damage HSCs, and/or chemotherapy, or have
not yet been exposed to such levels of radiation, and/or
chemotherapy. The subject in need thereof preferably has
normal levels of latexin expression in their bone marrow. In
one embodiment the subject in need thereof has a solid
tumor and is either already receiving chemotherapy and/or
radiation therapy, or is scheduled to start chemotherapy
and/or radiation therapy. In another embodiment, the subject
in need thereof is likely to be exposed to radiation therapy
and/or chemotherapy or a chemotherapeutic agent. The
present methods include providing a pharmaceutical composition prior to exposure to radiation and/or chemotherapy/
chemotherapeutic agent in order to protect the HSCs from
damage caused by the radiation and/or chemotherapy/chemotherapeutic agent.
Protection against damage to HSCs is indicated, e.g., by
an increase in the overall survival of the subject, by protecting the cells from DNA damage caused by the chemotherapy and/or radiation, by a decrease in the frequency of
HSC apoptosis, and/or by an increase in HSC proliferation
within the bone marrow of the subject.
The pharmaceutical composition useful in the methods
described herein comprises a therapeutically effective
amount of the latexin antagonist. The pharmaceutical composition may further comprise a pharmaceutical excipient
known by persons skilled in the art. Pharmaceutical formulations for effective delivery of pharmaceutical composition
will vary depending on the Latexin antagonist and mode of
administration. Suitable pharmaceutical excipients and carriers are known by persons skilled in the art (Remington's
Pharmaceutical Sciences (1989), which is incorporated in
entirety). Pharmaceutical compositions and formulations
can be administered by various methods, including by
injection, oral administration, inhalation, transdermal application, or rectal administration. For oral administration,
suitable formulations containing a pharmaceutical compound and pharmaceutically-compatible carriers can be
delivered in various forms, such as tablets or capsules, liquid
solutions, suspensions, emulsions, and the like. For inhalation, suitable formulations containing a pharmaceutical
compound and pharmaceutically-compatible carriers can be
delivered as aerosol formulations that can be placed into
pressurized propellants, such as dichlorodifluoromethane,
propane, nitrogen, and the like. For parenteral administration, suitable formulations containing a pharmaceutical
compound and pharmaceutically-compatible carriers can be
delivered by intra-articular, intra-venous, intramuscular,
intra-dermal, intra-peritoneal, and sub-cutaneous routes.
Pharmaceutical compositions suitable for use include
compositions containing a latexin antagonist in a therapeutically-effective amount to achieve its intended purpose.
More specifically, a therapeutically-effective amount of the
latexin antagonist means an amount effective to protect
HSCs from the damage caused by exposure to ionizing

radiation and/or chemotherapy. Determination of the effective amounts is well within the capability of persons skilled
in the art. A dose can be formulated in animal models to
achieve a circulating concentration range that includes IC50
value, defined as a dose in which 50% of cells of a culture
show an effect due to the test compound. Such information
can be used to more accurately determine useful doses in
human subjects.
Toxicity and therapeutic efficacy of latexin antagonists
can be determined by standard pharmaceutical procedures
utilizing cell cultures or experimental animals in order to
determine a LD50 value, the dose determined to be lethal to
50% of the exposed population, and to determine a ED50
value, the dose determined to be therapeutically effective in
50% of the exposed population. A dose ratio between toxic
effect and therapeutic effect is referred to as the "therapeutic
index," or it can be expressed as the ratio of the LD50 value
over the ED50 value. Compounds that exhibit high therapeutic indices are preferred. The data obtained from cell
culture assays and animal studies can be used in formulating
a range of effective dosage for human usage. Optimal dosage
range includes a ED50 dose with minimal toxicity, although
the dosage may vary within this range depending on a given
pharmaceutical formulation and route of administration.
Dosage administered to a subject should be adjusted according to the age of the subject, the weight of the subject, the
manner of administration, and other circumstances unique to
each subject.
Exemplary Antagonists that Inhibit the Expression and/or
Activity of Latexin and Latexin IsoformsNariants
A HSC population obtained from a donor can be induced
to proliferate ex vivo under in vitro conditions, or an
endogenous HSC population within a patient can be induced
to proliferate in situ by exposing the HSC population of
interest to various antagonists that can inhibit Latexin gene
expression and/or Latexin activity.
Suitable antagonists that can inhibit the expression and/or
the activity of Latexin and Latexin variants include
sequence-specific polynucleotides that can interfere with the
transcription of endogenous Latexin gene; sequence-specific
polynucleotides that can interfere with the translation of
Latexin mRNA transcripts (e.g., siRNAs, ribozymes);
sequence-specific polypeptides that can interfere with (a) the
protein stability of Latexin, (b) the enzymatic activity of
Latexin, and/or (c) the binding activity of Latexin with
respect to substrates and/or regulatory proteins; antibodies
that exhibit specificity for Latexin; and small molecule
compounds that can interfere with the protein stability of
Latexin, the enzymatic activity of Latexin, and/or the binding activity of Latexin. An effective antagonist can promote
HSC proliferation by at least 25%, 30%, 35%, 40%, 45%,
50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%,or
100%, preferably by 25% to 75%, more preferably 25% to
50%.
Sequence-Specific Compounds
In one embodiment, various interfering RNAs (RNAi)
that are complementary to human Latexin mRNA and mammalian orthologs can be employed by persons skilled in the
art to protect HSCs from the damage caused by ionizing
radiation and/or chemotherapy. By introducing such RNAi
compounds to a recipient subject that has been or will be
exposed to ionizing radiation therapy, ionizing radiation of
levels sufficient to damage HSCs, and/or chemotherapy, the
silencing or inactivation effect of RNAi compounds on
Latexin gene/gene products within the HSCs can protect
HSCs from the damage caused by ionizing radiation and/or
chemotherapy.
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Because introduction of double-stranded RNA
("d5RNA") that are longer than 30 nucleotides into mammalian cells induces a sequence-nonspecific interferon
response, alternative methods for delivery of interfering
RNA molecules ("RNAi") may be suitable. For example,
most common form ofRNAi molecules are short-interfering
RNAs ("siRNAs") of21-23 base-pairs that are chemically or
enzymatically synthesized, which can be introduced into
mammalian host cells by various methods, including transfections. However, unlike fungi, plants, and worms that can
replicate siRNAs in vivo, transfection of siRNA produces
only transient gene-silencing effect in mammalian cells. As
an alternative, DNA vectors encoding precursor-like forms
of siRNAs may be used for stable production of siRNAs in
vivo in various cells, including mammalian cells.
In another embodiment, the compounds that protect HSCs
from the damage caused by ionizing radiation and/or chemotherapy comprise an oligonucleotide that can interact
with endogenous messenger RNA encoded by Latexin gene
or by Latexin isoforms having at least about 70%, 75%,
80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence
similarity to SEQ ID NO: 1 (i.e., a sense-strand of human
Latexin cDNA). Such RNA oligonucleotide compounds can
be single-stranded or double-stranded. Suitable lengths of
RNA oligonucleotides include molecules containing 15-20
nucleotides, 20-30 nucleotides, 30-50 nucleotides, 50-75
nucleotides, 75-100 nucleotides, 100-150 nucleotides, 150200 nucleotides, and 200-300 nucleotides. In another
embodiment, the antagonist of latexin that can protect HSCs
from the damage caused by ionizing radiation and/or chemotherapy include an anti-sense strand that can hybridize to
an endogenously produced messenger RNA, and that can
inhibit the translation of the messenger RNA.
Selection of effective siRNAs useful in the methods of
this invention is based on certain known rules governing
optimal selection of siRNAs. For example, siRNAs containing sequence motifs, such as AAN 19TT, NAN 19 NN,
NARN 1 7 YNN, and NANN 17YNN, are effective, in which N
is any nucleotide, R is a purine, and Y is a pyrimidine. In
addition, regions of complementary DNA should have nonrepetitive sequences, and should avoid intronic sequences.
Suitable siRNAs contain approximately 30-70% GC content, contain even representation of all nucleotides on the
antisense strand, and do not contain stretches of single
nucleotide, especially stretches of Gs. Designing suitable
siRNA molecules is within the scope of persons skilled in
the art. The following references are herein incorporated by
reference in their entirety: Henschel et al. Nucleic Acids
Research, Vol. 32: 113-120 (2004); Naito et al. Nucleic
Acids Research, Vol. 32: 124-129 (2004); Dorsett et al. Vol.
3: 318-329 (2004); and Brummelkamp et al. Nature
Reviews, Vol. 3: 781-789 (2003); Pusch et al. Nucleic Acid
Research, 31: 6444-6449 (2003); and Chiu et al. RNA 9:
1034-1048 (2003).
Although any region of mRNA can be theoretically targeted, certain sequences that are known binding sites for
mRNA-binding proteins should be avoided, including
untranslated regions, such as the "5'UTR" and "3'UTR,"
start-codons, and exon-exon boundaries. For some mRNA
targets, siRNA-directed silencing may be more effective if
the mRNA targeted siRNA sequence is selected at least
50-100 nucleotides downstream of a start codon, and preferably directed towards the 3' end of a target mRNA. In
addition, the conformation of an mRNA recognition site
within an mRNA target is preferably RNAse-H-sensitive,
and preferably not within a highly-structured RNA region.
These guidelines are generally applicable since the choice of

a siRNA depends on the target mRNA sequence, and persons
skilled in the art would only need to synthesize several
siRNAs to validate the efficiency of each. The specificity of
a siRNA for a single gene can be ascertained by performing
a multiple genome-sequence alignment; such as a BLAST
search of the selected sequence against sequence databases,
including "Unigene" libraries associated with National Center for Biotechnology Information (NCBI). Potential offtarget silencing by siRNA may be minimized by choosing a
siRNA sequence with maximum sequence divergence from
a list of genes with partial-sequence identity to the intended
mRNA target. General principles for siRNA selection are
taught by the following two review articles, which are
incorporated by reference (Dorsett and Tuschl, Nature
Reviews Vol. 3: 318-329, (2004); Dykxhoorn et al. Nature
Reviews Vol. 4: 457-467 (2003)).
Various expression vectors can be constructed to enable
stable production of siRNA-like molecules in vivo. For
example, RNA-pol II promoters may be operably-linked to
a hairpin precursor of a siRNA sequence of interest. RNApol II promoters represent a broad range of promoters that
enable substantial control over parameters governing RNA
expression, such as inducible, constitutive, tissue-specific,
or developmentally-regulated RNA expression. Alternatively, RNA-pol III promoters may be used to produce short
RNA species that do not activate the interferon pathway.
Suitable RNA-pol III promoters include class III promoters
that lack essential transcriptional elements downstream of a
transcription initiation site, such as U6 and Hl promoters,
which may be operably-linked to a siRNAencoding
sequence.
Long-hairpin RNAs, imperfect shRNAs, miRNAs, and
siRNAs, to be used in the present methods can be designed
as follows. For example, a sub-sequence of a messenger
RNA encoded by Latexin gene or by Latexin isoforms
having at least about 70%, 75%, 80%, 85%, 90%, 95%,
96%, 97%, 98%, or 99% sequence similarity to SEQ ID
NO:1 (i.e., a sense-strand of human Latexin cDNA), can be
targeted. For example, an anti-sense strand of shRNA can be
designed by selecting a sub-sequence portion of a RNA
sequence complementary to endogenous Latexin messenger
RNA and Latexin isoforms having at least about 70%
sequence similarity to SEQ ID NO: 1.
For designing siRNA, the composition and size of the
loop and length of the stem of a hairpin duplex should be
considered. Suitable stem lengths for efficient silencing
include a broad range, including stem lengths of 19-29
nucleotides. Suitable loop lengths for efficient silencing
include a broad range, including loop lengths of 4-23
nucleotides. In certain context, hairpin structures with
duplexed regions that are longer than 21 nucleotides may
promote effective siRNA-directed silencing, regardless of
loop sequence and length.
Various gene-delivery vectors that are practiced by persons skilled in the art can be used to introduce the present
expression vectors. Examples of viral vectors that may be
used to infect HSC cells include: improved adenoviral
vectors (Reynold et al. Nature Biotechnology 19: 838-842
(2001)); gene-deleted adenovirus-transposon vectors (Yant
et al. Nature Biotechnology 20: 999-1005 (2002)); recombinant adenoviruses (Bilang-Bleuel et al. Proc. Natl. Acad.
Sci. U.S.A. 94: 8818-8823 (1997)); the Moloney-murineleukemia-virus ("Mo-MuL V") based retroviral vectors
(Auten et al., Human Gene Therapy 10: 1389-99 (2003));
and poliovirus-replicon-based vectors (Bledsoe et al.,
Nature Biotechnology 18: 964-969 (2000)). Examples of
other suitable viral vectors include: herpes virus, mumps
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virus, Sindbis virus, vaccinia virus, such as the canary pox
virus, and lentivirus. The usage of viral vectors is well
known by persons skilled in the art, and for gene therapy
uses, viral infection is preferred generally. The following
references are incorporated by reference in their entirety:
Robbins and Ghizzani, Mo!. Med. Today 1:410-417 (1995);
Robin et al. Stem Cells 20:514-521 (2002); Chen et al.,
Immunity 19:525-533 (2003); North et al. Immunity 16:
661-672 (2002); Zhou et al., Nature Medicine 7: 1028-1034
(2001); Ivanova et al. 298: 601-604 (2002); and Santos et al.
Science 298: 597-600 (2002).
In one embodiment, various oligodeoxyribonucleic acid
(ODN) molecules that are complementary to endogenous
messenger RNA encoded by Latexin gene or by Latexin
isoforms having at least about 70%, 75%, 80%, 85%, 90%,
95%, 96%, 97%, 98%, or 99% sequence similarity to SEQ
ID NO: 1 (i.e., a sense-strand of human Latexin cDNA), can
be employed by persons skilled in the art to protect HSCs.
By introducing such oligodeoxyribonucleic acid (ODN)
molecules to a recipient subject that has been or will be
exposed to ionizing radiation and/or chemotherapy, the
silencing or inactivation effect of RNAi compounds on
Latexin gene/gene products within the HSCs can protect
HSCs from the damage caused by ionizing radiation and/or
chemotherapy. Suitable oligodeoxyribonucleic acid mo!ecules ("ODN s") are short polynucleotides of approximately
20 nucleotides in length that can hybridize with pre-mRNA
and mRNA to form RNA-DNA duplexes, which are
degraded by ribonuclease H ("RNase H"). Such ODNs can
be chemically modified to prevent the action of RNase H, to
inhibit translation of mRNA by steric hindrance, to inhibit
splicing of pre-mRNAs, and to inhibit transcription by the
formation of triple helices. Kurreck, J. et al., Eur. J. Biochem., 270:1628-1644 (2003); Baker et al., J. Biol. Chem.,
272:11994-2000 (1997); Lu, Q. L. et al, Nature Med.,
9:1009-1014 (2003); and Uil, et al., Nucleic Acids Res.,
31:6064-6078 (2003) are incorporated by reference in their
entirety.
In one embodiment, various ribozymes containing
sequences that are complementary to endogenous messenger
RNA encoded by Latexin gene or by Latexin isoforms
having at least about 70%, 75%, 80%, 85%, 90%, 95%,
96%, 97%, 98%, or 99% sequence similarity to SEQ ID NO:
1 (i.e., a sense-strand of human Latexin cDNA), can be
employed by persons skilled in the art in order to reduce
Latexin expression and/or Latexin activity that results in the
protection of HSCs from the damage caused by ionizing
radiation and/or chemotherapy. Ribozymes, including the
"hammer-head" ribozyme, are RNA molecules that bind
target mRNA by assuming a unique secondary structure
when hybridized to target mRNA, which enables catalytic
hydrolysis of a phosphodiester bond within in the backbone
of target mRNA. Efficient cleavage by a ribozyme requires
the presence of divalent ions, such as magnesium, and is also
dependent on target RNA structure, and relative proximity
between ribozyme and target molecule. RNA localization
signals or RNA chaperones may be used so that low concentrations of ribozymes are sufficiently effective in silencing Latexin and Latexin isoforms. Ribozymes can be chemically synthesized in vitro, and can be transcribed from
expression vectors in vivo. Methods for ribozyme construction and utilization are known by persons skilled in the art.
Doudna and Cech, Nature, 418:222-228 (2002); Kuwahara
et al. J. Biochem., 132:149-155 (2002); Michienzi and
Rossi, Methods Enzymol. 341:581-596 (2001); and Good et
al. Gene Ther. 4:45-54, (1997) are herein incorporated by
reference.

In another embodiment, suitable antagonists include small
molecules that can bind polypeptides having at least about
70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%
sequence similarity to SEQ ID NO:2, that can inhibit the
activity of the bound polypeptide, and that can promote the
proliferation of HSCs and/or suppress the apoptosis of
HSCs. In addition, small molecules that can interact with
genomic DNA containing exons having at least about 70%,
75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%
sequence similarity to SEQ ID NO:1 (i.e., a sense-strand of
human Latexin cDNA) can be employed. In addition, compounds that can interact with RNA transcripts encoded by a
gene, in which the exon sequences have at least about 70%,
75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%
sequence similarity to SEQ ID NO:1 (i.e., a sense-strand of
human Latexin cDNA) can be employed. Various compounds that can inhibit the expression and/or activity of
Latexin or Latexin isoforms can be either naturally-occurring or synthetically-produced. Large combinatorial libraries
of chemical/biological compounds can be generated by
various chemical and biological synthesis methods known in
the art. Such combinatorial chemical libraries include: small
organic molecule libraries (benzodiazepines, Baum C&EN,
January 18, page 33 (1993)); Chen et al. J. Amer. Chem. Soc.
116:2661 (1994)), such as isoprenoids (U.S. Pat. No. 5,569,
588), thiazolidinones and metathiazanones (U.S. Pat. No.
5,549,974), pyrrolidines (U.S. Pat. Nos. 5,525,735 and
5,519,134), morpholino compounds (U.S. Pat. No. 5,506,
337), and benzodiazepines (U.S. Pat. No. 5,288,514), oligocarbamates (Cho et al. Science 261:1303 (1993)), and
peptidyl phosphonates (Campbell et al., J. Org. Chem.
59:658 (1994)). Exemplary combinatorial libraries include:
various peptide libraries (U.S. Pat. No. 5,010,175; Furka,
Int. J. Pept. Prat. Res. 37:487-493 (1991); Houghton et al.,
Nature 354:84-88 (1991)); peptoid libraries (PCT Publication No. WO 91/19735); encoded peptides (PCT Publication
No. WO 93/20242); random bio-oligomers (PCT Publication No. WO 92/00091); benzodiazepines (U.S. Pat. No.
5,288,514); diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs et al., Proc. Nat. Acad. Sci.
USA90:6909-6913 (1993)); vinylogous polypeptides (Hagihara et al., J. Amer. Chem. Soc. 114:6568 (1992)); nonpeptidal peptidomimetics with glucose scaffolding (Hirschmann
et al. J. Amer. Chem. Soc. 114:9217-9218 (1992)); various
nucleic-acid libraries; various peptide-nucleic acid libraries
(U.S. Pat. No. 5,539,083); various carbohydrate libraries
(Liang et al., Science, 274:1520-1522 (1996); U.S. Pat. No.
5,593,853)); and various antibody libraries (Vaughn et al.,
Nature Biotechnology, 14(3):309-314 (1996)).
Targeting Functionally-Related Isoforms of Latexin
The present methods and compositions can be employed
for targeting variants of Latexin that have similar properties/
activities within HSCs of many types of mammalian subjects. Functionally-related isoforms of Latexin can be identified by searching various genomic databases and
conducting multi-genome-wide sequence alignments in
order to identify homologous sequences of interest. Related
orthologous sequences can be identified by searching composite genomic databases. The breath of a database search is
limited by the scope of representative model organisms for
which sequence data is available.
Homology can be determined by various routine methods,
including alignments of open-reading-frames ("ORF s") contained in private and/or public databases. Any suitable
mathematical algorithm may be used to determine percent
identities and percent similarities between any two
sequences being compared. For example, nucleic acid and
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protein sequences of the present invention can be used as a
"query sequence" to perform a search against sequences
deposited within various public databases to identity other
family members or evolutionarily-related sequences.
Genomic sequences for various organisms are currently
available, including fungi, such as the budding yeast, or
Saccharomyces cerevisiae; invertebrates, such as Caenorhabditis elegans and Drosophila melangaster; and mammals, such as the mouse, rat, and human. Exemplary databases for identifying orthologs of interest include Genebank,
Swiss Protein, EMBL, and National Center for Biotechnology Information ("NCBI"), and many others known in the
art. These databases enable a user to set various parameters
for a hypothetical search according to the user's preference,
or to utilize default settings. Tables 1-3, provided below, list
the accession numbers and gene identification numbers for
exemplary manmialian orthologs. Suitable Latexin variants
that may be targeted for suppression or inhibition includes
e.g, the variants of SEQ ID NO: 1 or SEQ ID NO: 2
described herein. In another embodiment, suitable Latexin
variants that may be targeted for suppression or inhibition
include variants of SEQ ID NO: 1 or SEQ ID NO: 2 other
than the carboxypeptidase inhibitor (CARIN) described in
U.S. Pat. No. 5,998,373.

TABLE 1
Gene Bank Accession Number for Exemplary Mouse, Hwnan, and Rat

Latexin mRNA.
5

Organism

Accession Nwnber

Gene IDS
31980631

Mus musulus (Mouse)

NM-016753

Rattus norvegicus (Rat)

NM-031655

14269567

Homo Sapiens (Human)

NM-020169

21359932

10

TABLE 2
15
Gene Bank Accession Number for Exemplary Mouse, Hwnan, and Rat
Latexin Protein.

20

Organism

Accession Nwnber

Gene IDS

Mus musulus (Mouse)
Rattus norvegicus (Rat)
Homo Sapiens (Human)

NP-058033
NP-113843
NP-064554

31980632
14269568
21359933

TABLE 3
Mammalian Homologs for Latexin.

Organism

Accession
Number

Gene IDS

Mus

AK032170.1

26327996

99.91

AK149981.1

74211713

100.00

1669620

99.50

AC124190.4

23499687

100.00

AC124190.4

23499687

100.00

AC124190.4

23499687

100.00

AC124190.4

23499687

100.00

AC124190.4

23499687

100.00

AC124190.4

23499687

100.00

AK018305.1

12857946

99.58

AK198791.1

56022968

100.00

Percentage
Identity Gene Information

musulus
(Mouse)

Mus
musulus
(Mouse)

Mus

D88769.1

musulus
(Mouse)

Mus
musulus
(Mouse)

Mus

Mus musulus adult male olfactory
brain cDNA, RIKEN full-length
enriched library, clone: 6430407E02
product: Latexin, full insert sequence
Mus musulus bone marrow
macrophage cDNA, RIKEN fulllength enriched library,
clone: G530111019
product: Latexin, full insert sequence
Mus musulus mRNA for Latexin,
complete eds

Mus musulus BAC clone RP23267M9 from 3, complete sequence

musulus
(Mouse)

Mus
musulus
(Mouse)

Mus
musulus
(Mouse)

Mus
musulus
(Mouse)

Mus
musulus
(Mouse)

Mus
musulus
(Mouse)

Mus
musulus
(Mouse)

Mus musulus 10 days neonate
cerebellum cDNA, RIKEN full-length
enriched library, clone: 6530401Al0
product: Latexin, full insert sequence
Mus musulus cDNA,
clone: Y1G0129D08, strand: minus,
reference: ENSEMBL: MouseTranscript-

ENST: ENSMUST00000058981,
based on BLAT search

US 10,604,756 B2
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TABLE 3-continued
Mammalian Homologs for Latexin.

Organism

Mus
musulus
(Mouse)

Accession
Number

Gene IDS

AK187030.1

56011207

99.52

6066618

94.33

6066618

96.92

Rattus
Y18435.2
norvegicus
(Rat)
Rattus
Y18435.2
norvegicus
(Rat)

Percentage
Identity Gene Information

Mus musulus cDNA,
clone: YOG0139J09, strand: minus,
reference: ENSEMBL:
Mouse-TranscriptENST: ENSMUST00000058981,
based on BLAT search
Rattus norvegicus Latexin gene, exons
1 to 6

Assays
Various assays measure the number and functionality of
HSCs and their progeny. These assays include in vitro
phenotyping assays, in vitro clonogenic assays, and in vivo
transplantation assays.
Flow cytometry reveals important information on the
phenotypes of different hematopoietic cell subsets. Combining fluorescently labeled antibodies against cell surface
receptors with flow cytometric analysis allows for the identification and isolation of progenitor and stem cells. Generally, there is a good correlation between the phenotype and
in vivo reconstitution potential of HSCs; under stress conditions (aging, chemo/radio therapy or transplantation), phenotypic isolation strategies vary in their efficiency in selecting HSCs.
The colony-forming unit (CFU) assay is an in vitro assay
widely used to detect and quantify hematopoietic progenitor
cells. In this assay, BM, spleen or peripheral blood cells are
mixed with methylcellulose-based medium supplied with a
combination of cytokines, and cultured for one or two
weeks. Progenitor cells of different lineages form colonies
which have distinct morphologies. In this assay, each colony
is counted and characterized by lineage according to their
morphologies. Thus, it offers insight into the lineage specificity of cells, rather than assessing the functional activity of
primitive, pluripotent HSCs.
The cobblestone-area forming cell (CAFC) assay is an in
vitro limiting-dilution assay used to determine the frequency
of hematopoietic cell subsets in a developmental hierarchy.
A stromal cell layer (e.g. FBMD-1 cells) is pre-seeded and
cultured in 96-well plates, and allows for in vitro long-term
culturing of stem and progenitor cell. After the stromal cells
reach confluency, bone marrow cells are plated on top of
them. The primitive HPCs (hematopoietic progenitor cells)
and HSCs will form the colony underneath the stromal cell
layer. The colonies are monitored and counted under the
microscope weekly for 5 weeks. The later the cells are in
forming the colony, the more primitive the cells are. That is,
cells forming colonies at early time-points (day 7, 14 and 21)
are different stages of HPCs, and those forming colonies at
day 28 and 35 are HSCs. CAFC day 35 cells are commonly
used to determine primitive HSCs. CAFC assay can be used
to determine the adhension capacity of HSCs to stromal
cells. In this assay, hematopoietic cells are plated onto a
stromal layer and the hematopoietic cells and stromal cells
are allowed to interact for 2-4 hours. The non-adherent cells
are then washed away, leaving the adherent cells in culture.
These adherent cells will form cobblestone-areas at later
time points. The adhesion assay generally measures the
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adhesive properties of hematopoietic cells and studies the
interaction between hematopoietic cells and stromal cells.
The CAFC assay is a reliable approach for measuring the
frequency and clonogenic function of hematopoietic progenitor and stem cells.
EXAMPLES
Animals
Young C57BL/6 (B6) mice (8-16 weeks) were purchased
from The Jackson Laboratories (Bar Harbor, Me.). Latexin
constitutive knockout mice were generated by Taconic/
Artemis (Germantown, N.Y.) and used at a young age (8-16
weeks). Male animals were used in this study. All animals
were housed in the animal facilities of the University of
Kentucky under pathogen-free conditions according to NIHmandated guidelines for animal welfare and were given food
and water ad libitum. Lxn constitutive knock-out mice were
used as a model and they were treated with ionizing radiation. The Lxn deficient mouse model was generated by
Taconic/armetis under contract let by the inventors. The
salient alteration was a deletion of Lxn exons 2-4 resulting
in a complete knockout of LXN synthesis.
Ionizing Radiation
The mice and cells were exposed to various doses of
radiation (6.5 Gy, 8 Gy, 9 Gy and split doses of 12 Gy) in
a 13 7 Cs ganima irradiatior (J. L. Shepherd and Associates,
Glendale, Ga.) at a dose rate of 153 rad/min.
Peripheral Blood Cell Counts
Animals were anesthetized with isoflurane (Butler Animal
Health Supply, Dublin, Ohio). Peripheral blood was collected from retro-orbital venous plexus into EDTA-coated
microtainer tubes (Becton, Dickinson and Company, Franklin Lakes, N.J.). Circulating leukocytes, erythrocytes and
platelets were counted by analyzing 20 µL of blood using a
Hemavet 950 (Drew Scientific, Dallas, Tex.).
Hematopoietic Cell Identification and Isolation
Bone marrow cells were flushed from the femora and
tibiae using a 1 ml syringe and 22G needle into Hanks
balanced salt solution (HBSS) with 2% fetal bovine serum
(FBS) (Gibco, Grand Island, N.Y.). Progenitor cells were
discriminated from stem cells by the lack of cell surface
antigens characteristic of cells committed to individual
lineages. Antibodies against these antigens included CDS
and CD8a, B220, Mac-1, Gr-1, and Ter119 were biotinylated. Strepavidin secondary antibody was used to detect
lineage negative cells. To further purify primitive stem cells,
the stem cell markers Sca-1 and c-Kit were incorporated into
the staining procedure. Dead cells were excluded by pro-
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pidium iodide (PI) that stains exposed double-strand DNA.
All monoclonal antibodies were purchased from eBioscience (San Diego, Calif.), Biolegend (San Diego, Calif.), or
BD Pharmingen (San Jose, Calif.).
Cell Analysis and Sorting
Bone marrow cells were analyzed and sorted on a BD
FacsAria II flow cytometer (Becton Dickinson, Franklin
Lakes, N.J.). Cells were sorted into phosphate buffered
saline (PBS) with 0.5% FBS for further use. Flow cytometry
data was analyzed using FlowJo software (Tree star, Ashland, Oreg.).
Apoptosis Analysis
Bone marrow cells were prepared and stained as
described above. The fluorochrome-conjugated apoptotic
marker Annexin V along with Propidium Iodide (PI) (both
from BD Pharmingen) were used to identify apoptotic cells
(PI-/Annexin V+). Stained cells from Lxn-/- animals and
B6 animals were analyzed by flow cytometer.
Colony Forming Cell (CFC) Assay
Methylcellulose-based culture media (MethoCult) was
purchased from Stem Cell Technologies, Vancouver, Canada
and contained the following cytokines: stem cell factor
(SCF), IL-3 and IL-6. For this assay, 5xl04 whole BM cells
in 100 µL HBSS were thoroughly admixed with 1 mL
complete MethoCult media, plated into petri-dishes, and
incubated at 37° C. Individual wells of duplicates were
counted on day 10 to quantify lineage specific colonies.

was significant greater than B6 mice before irradiation and
3 days after exposure to irradiation (FIG. 2A). LSK cell
counts dropped dramatically at day 7 in both experiment
groups. However, the HSC recovery rate was accelerated in
Lxn-/- mice.
The number ofLSK cells compartment increased approximately 6-fold at day 14 and 3-fold at day 21 in Lxn-/- mice
(FIGS. 2A and B). The numbers ofLK (Lin-/c-Kit+/Sca-1-)
and LS (Lin-/c-Kit-/Sca-1 +) cells were also increased at
day 14, though not to the same extent of LSK cells. These
data indicate that deletion ofLxn selectively protects primitive cells more so than differentiated cells (FIG. 2B).
In flow cytometric analysis, phenotypic markers were
used to quantify HSPC numbers. To further identify the
numbers of functional HSPCs, CFU assays were performed
with 5xl04 whole BM cells from 6.5 Gy sub-lethally irradiated animals. The pattern of HSPC recovery in Lxn-/mice is similar to that pattern observed when using phenotypic markers.
Lxn-/- whole BM cells from mice at day 0, 1, 3, 14 and
28 post irradiation formed significantly more colonies,
which indicated an accelerated recovery rate compared to
B6 cells (FIG. 2C). This observation supported previous
LSK cell population frequency results.
A similar trend in BM cell recovery was also observed.
The numbers of surviving whole BM cells were significantly
diminished (24-28 million cells per femur to less than 3
million cells per femur) shortly after irradiation (day 3), and
subsequently stable returned back to normal levels by day 28
in Lxn-/- mice (FIG. 2D). Lxn-/- BM cells showed an
accelerated recovery rate over B6 BM cells at day 7, 14 and
28 (FIG. 2D), in accordance with increased tempo in recovery of HSPCs (FIG. 2A).
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Lxn Function in Response to Hematopoietic
Stress-induced Apoptosis

Example 3
The effects of loss of Lxn in BM cell radiation resistance
were studied first. Total body irradiation (TBI) was administered to Lxn-/- mice and to B6 control mice. Various
dosages of gamma radiation including lethal doses of 8 Gy
and 9 Gy were tested, as well as clinically relevant split
doses totaling 12 Gy. The survival rate for each treatment
was then tested. All of the lethally irradiated B6 animals died
within 20 days after receiving a single 8 or 9 Gy dose (FIG.
lA). Surprisingly, the survival rate of Lxn-/- mice was
significantly greater. As shown in FIG. lA, 60% of the
Lxn-/- mice survived the 8 Gy dose of irradiation and 20%
of Lxn-/- mice survived the 9 Gy dose.
To further characterize the radio-protective effect and
study its implication in medical treatment, two experimental
groups were irradiated with 12 Gy TBI using a fractionated
schedule of2 Gy every 12 hours. 80% ofLxn-/- mice (4 out
5) survived over 600 days whereas only 20% of WT control
mice (1 out 5) survived. The difference is significant
(p<0.05). (FIG. 18)
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HSC and HPC Recovery after Radiation Exposure
A single dose of 6.5 Gy TBI (sub-lethal dose) was
administered to both experimental groups (Lxn-/- mice and
wild-type B6 mice). The recovery ofHSPC post irradiation
was determined by both flow cytometer (which counts
phenotypic HSPC) and in vitro colony-forming unit (CFU)
assay (which measures functional HSPC) in a time dependent manner. At each time point, BM cells were harvested,
BM cellularity was analyzed, and the size of the surviving
LSK cell population in both groups was measured. The
number ofphenotypic HSPCs (LSK cells) in Lxn-/- mice

60
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Hematologic and Immune Recovery
Because radiation-induced hematological failure and
immune failure are the primary causes of low survival after
high dose radiation exposure, hematologic and immune
recovery in a time dependent manner following radiation
exposure were examined.
Wild type B6 and Lxn-/- animals were exposed to a
sub-lethal (6.5 Gy) dose of radiation to trigger reversible
hematopoietic injury, and the rate ofrecovery of blood cells
was monitored.
As demonstrated in FIG. 3A, loss of Lxn significantly
accelerated the recovery of total leukocytes in blood.
Untreated Lxn-/- mice have -30% more leukocytes than
their wild type counterparts (FIG. 3A).
Leukocytes in both strains dropped to approximately
1,000 cells/µL in peripheral blood one day after irradiation.
The number of Lxn-/- leukocytes rapidly recovered at day
7 and remained significantly greater than B6 (approximately
100% more) up to day 14. The counts of neutrophils (FIG.
3B) and lymphocytes (FIGS. 3B and 3C) had similar recovery patterns as the total leukocytes. Lxn-/- mice showed a
faster recovery over the period from day 7 to 28 compared
to B6 animals.
The level of neutrophil counts in both groups overshot
normal levels, whereas lymphocytes never fully recovered.
Platelet (FIG. 3D) counts in both groups recovered to normal
by day 28. The number ofLxn-/- platelets was significantly
greater than B6 platelets 3-7 after irradiation.
Collectively, a significant recovery advantage was
observed at multiple time points in both hematologic and
immune systems in PB, possibly resulting from accelerated
recovery in HSPCs in BM.
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The lineage distribution of mature blood cells between
granulocyte, monocyte, T-cell and B-cell lymphocytes using
various lineage markers were also studied. The gamma
irradiation caused immediate lympho- and myelo-ablation at
day 1 and an altered lineage distribution that favored the
myeloid lineage (FIG. 3E). The lymphoid lineage started to
gradually recover 3 days after radiation.
The distribution ofB lymphocytes in Lxn-/- mice recovered to near normal (50%), but B6 B lymphocytes never
fully recovered (30%) (FIG. 3E).
In sum, the recoveries of total leukocyte, platelet, granulocyte and lymphocyte subsets were significantly accelerated in Lxn-/- mice following ionizing radiation. Further,
Lxn-/- cells favor B cell lineage production in long-term
reconstitution.

was significantly lower in Lxn-/- mice after 6.5 Gy sublethal irradiation (FIG. 4A). During homeostasis, apoptotic
cell frequency is inherently significantly lower in Lxn-/LSK cells (day O in FIG. 4A). This low apoptotic frequency
was sustained from day 7 to day 28 after irradiation. On day
14 the percentage of apoptotic LSK cells was 5-fold lower
in Lxn-/- mice compared to B6 mice (FIGS. 4A, 4B and
4C). Notably, the percentage of apoptotic cells in Lin-, LK
and LS subpopulations diminished along with Lxn ablation
on day 14, but did not reach statistical significance (FIG.
4C). The apoptotic frequency was significantly reduced only
in LSK cells, indicating that loss of Lxn selectively affected
the apoptotic rate in primitive BM cells.
It will be appreciated that, although specific embodiments
of the invention have been described herein for purposes of
illustration, various modifications may be made without
departing from the spirit and the scope of the invention.
Accordingly, the invention is not limited except as by the
appended claims.
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Example 4
Apoptotic Frequency
Apoptotic frequency was directly examined using
Annexin V staining. The percentage of apoptotic LSK cells
SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS,
<210>
<211>
<212>
<213>

SEQ ID NO 1
LENGTH, 1113
TYPE, DNA
ORGANISM, human

<400>

SEQUENCE, 1

2

agaageagte ageeeaggge teteggatge agggageetg ggcccaaaca geagetteeg

60

gagteggaag gagetgagga agaagacaga etgaaggage ttgegaettt teegeetegg

120

caaccggacc cagcagcaag eaggaeggge ggegetetge taetggteee gttaageeag

180

agtagcccaa geeetgaagt cactgctcat eeggaatgga aatcccgccg accaactacc

240

cagcctccag ggeggeettg gtggeaeaga actacatcaa ctaccagcag gggaeeeege

300

aeagggtgtt tgaggtgeag aaggtcaaac aagccagcat ggaggatatt eeaggaagag

360

gacataagta tcgccttaaa tttgetgttg aagaaattat acaaaaacaa gttaaggtga

420

actgcacagc tgaagtaett tacccttcaa egggaeaaga aactgcacca gaagtcaact

480

tcacatttga aggagaaaet ggaaagaate eagatgaaga agacaacaca ttttatcaaa

540

gaettaagte eatgaaggaa eegetagaag cacaaaatat tccagacaat tttggaaatg

600

tatctccaga aatgacgctc gttetaeatt tageetgggt tgeetgtggt tatataatat

660

ggcaaaattc tactgaagac aeatggtata aaatggtaaa aattcaaact gteaageaag

720

tgcaaagaaa tgatgaettt attgaattag actacaccat tctacttcat aatatagcat

780

eteaggagat tatteeetgg caaatgcaag ttetetggea tccacaatac ggeaetaaag

840

taaaacataa tageegtetg ccaaaggaag tacaactgga ataaacaaaa accctaacac

900

tggaagtgta aacatgtcta ttgatgtgta tgccaatttc aetggeatet agettatgag

960

gccaaataat cccaaagtgt cactttatat aaatgtettg attacagtat agaactttat

1020

agagtccata atacaaagta tcactacata aaaatgtctt taaaacagta atagtggtat

1080

gtatatccaa aataaaaagc ttcaatttca gee

1113

<210> SEQ ID NO 2
<211> LENGTH, 222
<212> TYPE, PRT
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-continued

<213> ORGANISM, human
<400> SEQUENCE, 2
Met Glu Ile Pro Pro Thr Asn Tyr Pro Ala Ser Arg Ala Ala Leu Val
1
5
10
15
Ala Gln Asn Tyr Ile Asn Tyr Gln Gln Gly Thr Pro His Arg Val Phe
20
25
30
Glu Val Gln Lys Val Lys Gln Ala Ser Met Glu Asp Ile Pro Gly Arg
35
40
45
Gly His Lys Tyr Arg Leu Lys Phe Ala Val Glu Glu Ile Ile Gln Lys
50
55
60
Gln Val Lys Val Asn Cys Thr Ala Glu Val Leu Tyr Pro Ser Thr Gly
65
70
75
80
Gln Glu Thr Ala Pro Glu Val Asn Phe Thr Phe Glu Gly Glu Thr Gly
85
90
95
Lys Asn Pro Asp Glu Glu Asp Asn Thr Phe Tyr Gln Arg Leu Lys Ser
100
105
110
Met Lys Glu Pro Leu Glu Ala Gln Asn Ile Pro Asp Asn Phe Gly Asn
115
120
125
Val Ser Pro Glu Met Thr Leu Val Leu His Leu Ala Trp Val Ala Cys
130
135
140
Gly Tyr Ile Ile Trp Gln Asn Ser Thr Glu Asp Thr Trp Tyr Lys Met
145
150
155
160
Val Lys Ile Gln Thr Val Lys Gln Val Gln Arg Asn Asp Asp Phe Ile
165
170
175
Glu Leu Asp Tyr Thr Ile Leu Leu His Asn Ile Ala Ser Gln Glu Ile
180
185
190
Ile Pro Trp Gln Met Gln Val Leu Trp His Pro Gln Tyr Gly Thr Lys
195
200
205
Val Lys His Asn Ser Arg Leu Pro Lys Glu Val Gln Leu Glu
210
215
220
40

The invention claimed is:
1. A method for protecting against hematopoietic stem
cell (HSC) damage caused by chemotherapy and/or radiation, the method comprising:
administering to a subject in need thereof a pharmaceutical composition comprising an siRNA that reduces
expression and/or activity of latexin,
wherein latexin is a latexin polynucleotide variant that
binds to the siRNA,
wherein the latexin polynucleotide variant has at least
95% sequence identity to SEQ ID NO: 1, and
wherein the latexin polynucleotide encodes a latexin
polypeptide variant that has at least 95% sequence
identity to SEQ ID NO: 2, and
wherein the subject in need thereof has a solid tumor and
is scheduled to start chemotherapy and/or radiation
therapy.
2. The method of claim 1, wherein the pharmaceutical
composition increases overall survival of the subject.
3. The method of claim 1, wherein the pharmaceutical
composition protects the HSCs from DNA damage.
4. The method of claim 1, wherein the pharmaceutical
composition decreases the frequency of HSC apoptosis.
5. The method of claim 1, wherein the pharmaceutical
composition promotes HSC proliferation by at least 25%.
6. The method of claim 1, wherein the damage is caused
to the bone marrow.
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7. A method for protecting against hematopoietic stem
cell (HSC) damage caused by chemotherapy and/or radiation, the method comprising:
administering to a subject in need thereof a pharmaceutical composition comprising an siRNA that reduces
expression and/or activity of latexin,
wherein latexin is a latexin polynucleotide variant that
binds to the siRNA,
wherein the latexin polynucleotide variant has at least
95% sequence identity to SEQ ID NO: 1, and
wherein the latexin polynucleotide encodes a latexin
polypeptide variant that has at least 95% sequence
identity to SEQ ID NO: 2, and
wherein the subject in need thereof has a solid tumor and
is already receiving chemotherapy and/or radiation
therapy.
8. The method of claim 7, wherein the pharmaceutical
composition increases overall survival of the subject.
9. The method of claim 7, wherein the pharmaceutical
composition protects the HSCs from DNA damage.
10. The method of claim 7, wherein the pharmaceutical
composition decreases the frequency of HSC apoptosis.
11. The method of claim 7, wherein the pharmaceutical
composition promotes HSC proliferation by at least 25%.
12. The method of claim 7, wherein the damage is caused
to the bone marrow.
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1_3. The metho_d _of claim 1, A method for protecting
agamst hematopmetJc stem cell (HSC) damage caused by
chemo~h~rap~ and/or radiation, the method comprising:
adm1mstenng to a subject in need thereof a pharmaceutical composition comprising an siRNA that reduces
expression and/or activity of latexin,
wherein latexin is a latexin polynucleotide variant that
binds to the siRNA,
wherein the latexin polynucleotide variant has at least
95% sequence identity to SEQ ID NO: 1, and
wherein the latexin polynucleotide encodes a latexin
polypeptide variant that has at least 95% sequence
identity to SEQ ID NO: 2, and
wherein the subject in need thereof is selected from the
group consisting of a subject receiving chemotherapy
and/or radiation therapy and a subject scheduled to start
chemotherapy and/or radiation therapy, and
wherein the subject in need thereof has normal levels of
latexin expression in his or her bone marrow.
14. The method of claim 13, wherein the pharmaceutical
composition increases overall survival of the subject.
15. The method of claim 13, wherein the pharmaceutical
composition protects the HSCs from DNA damage.
16. The method of claim 13, wherein the pharmaceutical
composition decreases the frequency of HSC apoptosis.
17. The method of claim 13, wherein the pharmaceutical
composition promotes HSC proliferation by at least 25%.
18. A method for treating bone marrow damage, the
method comprising:

administering to a patient in need thereof a pharmaceutical composition comprising an siRNA that reduces
expression and/or activity of latexin,
wherein latexin is a latexin polynucleotide variant that
binds to the siRNA,
wherein the latexin polynucleotide variant has at least
95% sequence identity to SEQ ID NO: 1, and
wherein the latexin polynucleotide encodes a latexin
polypeptide variant that has at least 95% sequence
identity to SEQ ID NO: 2, and
wherein the subject in need thereof is selected from the
group consisting of a subject receiving chemotherapy
and/or radiation therapy and a subject scheduled to start
chemotherapy and/or radiation therapy, and
wherein the subject in need thereof has a solid tumor and
wherein the bone marrow damage is caused by chemotherapy and/or radiation therapy.
19. The method of claim 18, wherein the pharmaceutical
composition decreases apoptotic frequency ofhematopoietic
stem cells (HSCs ).
20. The method of claim 18, wherein the pharmaceutical
composition promotes HSC proliferation.
21. The method of claim 20, wherein the pharmaceutical
composition promotes HSC proliferation by at least 25%.
22. The method of claim 18, wherein the subject in need
thereof is already receiving chemotherapy and/or radiation
therapy.
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